The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...
Verzenio showed promising efficacy in high-grade meningiomas with CDK pathway or NF2 alterations, achieving progression-free survival at six months in 14 of 24 patients. Patients with NF2 alterations ...
Deal activity, strategic funding and exploration momentum drove strong moves across small cap resources stocks on Friday. ...
Students celebrate at the end of basketball club at Adams Elementary School on Dec. 5, 2025. The Spokane district has ...
In December 2025, the Company also completed an underwritten Nasdaq capital raise, pricing ~2.93 million ADS’s at ~US$6.83 ...
The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...
Scheduled for May 4-15, submissions are currently being sought for what will be a two-week series of events designed to spark ...
In 2026, VARON continues to focus on clarity, reliability, and long-term user support. By offering a clearly structured lineup--from high-performance portable devices to clinical-grade home ...
A cornerstone of this initiative is MyBank, Bybit’s new retail banking layer targeting to launch in February 2026. MyBank ...
Small caps lit up as Apollo rocketed on the reinstatement of its French tungsten project. Meanwhile, Terra Metals confirmed a ...
The medical equipment manufacturer published a consumer guide to selecting appropriate oxygen therapy devices, highlighting ...
BNY Mellon Core Plus Fund Class I returned 1.04% in Q4 2025. Explore our full market commentary and credit outlook now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results